Status:
NOT_YET_RECRUITING
Prediction of Venous Thrombosis During chemotherapy-the PINPOINT Study
Lead Sponsor:
University of Dublin, Trinity College
Collaborating Sponsors:
Cork University Hospital
Mater Misericordiae University Hospital
Conditions:
Venous Thromboembolism
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Cancer patients are at higher risk of getting a blood clot (known as venous thromboembolism (VTE)) especially during chemotherapy and some patients are more at risk than others. These clots can be pre...
Detailed Description
Background: VTE is the leading cause of death in cancer patients after the cancer itself. Amongst solid tumours, pancreatic, lung, brain, stomach, and ovarian cancer are the most prothrombotic and ar...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of ovarian, lung, gastric or pancreatic cancer scheduled to undergo a course of chemotherapy who are undergoing adjuvant or neoadjuvant chemotherapy, or who are undergoing chemotherapy for relapsed disease or patients receiving targeted therapy in combination with chemotherapy
- Patients who are over 18 years of age
- Patients who are able to give full and informed written consent
Exclusion
- Prior history of a documented VTE event within the last 5 years (excluding central line associated events whereby patients completed anticoagulation \> 3 months previously)
- Any history of significant haemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 5 years
- Familial bleeding diathesis
- Known diagnosis of disseminated intravascular coagulation.
- Surgery within 2 weeks of first baseline sample (with the exception of porth-a-cath implantation or biopsy)
- Chemotherapy or immunotherapy 4 weeks before first baseline sample
- Currently receiving long term anticoagulant therapy (Low Molecular Weight Heparin(LMWH), Direct Oral Anticoagulants(DOACs), Warfarin). Patients receiving aspirin, ticlopidine, clopidogrel or LMWH at a prophylactic dosage for a short period (ie post cancer surgery or during short hospital stay) will be included provided they have completed thromboprophylaxis therapy at the first blood sampling time point.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2029
Estimated Enrollment :
380 Patients enrolled
Trial Details
Trial ID
NCT07196020
Start Date
October 1 2025
End Date
September 1 2029
Last Update
September 29 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Cork University Hospital
Cork, Ireland, T12 DC4A
2
Mater Misericordiae University Hospital
Dublin, Ireland, D07R2WY
3
Trinity Cancer St. James Cancer Institute
Dublin, Ireland, D08W9RT